StockWatch
·

AJANTA PHARMA LTD.

BSE: 532331

P/L Snapshot

Q2 FY27 · standalone

vs Q1 FY27·vs Q2 FY26
Revenue
1.8K
+14.0%+37.2%
Expenditure
1.3K
+10.5%+28.9%
Net Profit
379.89
+20.4%+52.2%
OPM %
29.98%
+3.33pp+6.25pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.00497.75995.511.5K2.0KQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q1 FY27Q2 FY27
Price Chart
Reports

Ajanta Pharma Q2FY27: consolidated PAT +49% YoY as margins beat guidance

pharmaceuticals · margin expansion · us generics growth

ResultsQ2 FY2730 Oct 20263 minPharma & Healthcare

Q2 FY27: Can Ajanta Hold Momentum as Seasons Shift?

pharma · generics · Q2 earnings

Result previewQ2 FY2724 Oct 20263 minPharma & Healthcare

Ajanta Pharma Q1: consolidated PAT up 31% to ₹334 Cr on 25% revenue jump, US +57%

pharma · branded generics · us generics

ResultsQ1 FY2730 Jul 20263 minPharma & Healthcare
Latest
Quarterly Result30 Oct, 12:56 pm

Ajanta Pharma Q2FY27: consolidated PAT +49% YoY as margins beat guidance

Consolidated PAT for Q2 FY27 came in at ₹388 Cr, up 49% YoY (₹260 Cr) and 16% QoQ (₹334 Cr), on revenue from operations of ₹1,794 Cr, up 33% YoY and 10% QoQ. Net profit margin expanded to 21.6% from 18.4% a year ago and 19.7% last quarter. Standalone PAT was ₹380 Cr, up 52% YoY — standalone and consolidated tell the same growth story with no material divergence. Neither this quarter nor the year-ago quarter carries an exceptional item, so the YoY growth is clean rather than base-effect driven. Segment-wise, US Generics led with revenue up 41% YoY to ₹484 Cr, Africa Institution (tender-driven) revenue jumped to ₹116 Cr from ₹32 Cr (+259% YoY), and India branded generics grew a steadier 16% YoY to ₹504 Cr — ahead of IPM industry growth of 13% per IQVIA MAT September 2026 data, against Ajanta's own 17% India branded growth. Gross margin held at 78.5%, within management's guided ~78%±1% band, while adjusted EBITDA margin (excluding forex) rose to 30% from 24.2% a year ago — above the ~27%±1% full-year EBITDA guidance given on the Q3 FY26 call. The expansion is broad-based across segments rather than a single cost-line effect. On the January 2026 concall, management had guided US generics to grow in double digits for FY27 but "not at the current robust pace" — this quarter's 41% YoY US print shows that expected deceleration has not materialised yet. No Q2-specific published Street consensus was found; full-year FY27 analyst consensus pegs revenue growth at roughly 15% YoY (₹6,270 Cr), a pace H1 FY27's 29% YoY growth is already running well ahead of. The quarter also saw routine promoter-level pledge/release filings (a 30,000-share pledge on Oct 21, a 2.10% stake pledge by CTL Trusteeship on Oct 1, an NCD-linked pledge on Oct 6, and a 98,185-share release on Sep 28) — financing-related disclosures unconnected to the operating numbers. With H1 FY27 EBITDA margin at 29.1% (₹997 Cr on ₹3,420 Cr revenue) already running above the ~27%±1% full-year band, and Africa Institution's tender revenue a known swing factor, the markers into H2 are whether the US growth pace decelerates as management itself flagged and whether the institutional-tender contribution normalises from this quarter's spike.

30 Oct 2026, 12:56 pm

Corporate Events

Board MeetingAJANTPHARM
2026
30Oct

Board Meeting

The meeting of the Board of Directors of the Company will be…

BSE Filing ↗
Board MeetingAJANTPHARM
2026
30Sep

Board Meeting

The Board has approved and taken on record Unaudited Financi…

BSE Filing ↗
DividendAJANTPHARM
2026
5Aug

Dividend

BSE Filing ↗
DividendAJANTPHARM
2026
5Aug

₹32 / share

BSE Filing ↗
Board MeetingAJANTPHARM
2026
30Jul

Board Meeting

The meeting of the Board of Directors of the Company will be…

BSE Filing ↗
Board MeetingAJANTPHARM
2026
16Jul

Board Meeting

The Forty-Seventh (47th) Annual General Meeting ("AGM") of t…

BSE Filing ↗
DividendAJANTPHARM
2025
10Nov

₹1 / share

BSE Filing ↗
Board MeetingAJANTPHARM
2025
3Nov

Board Meeting

Update on board meeting, declaration of interim dividend, fi…

BSE Filing ↗
DividendAJANTPHARM
2024
8Dec

₹2 / share

BSE Filing ↗
DividendAJANTPHARM
2024
6Nov

₹1 / share

BSE Filing ↗
Board MeetingAJANTPHARM
2024
28Oct

Board Meeting

Consider and approve unaudited consolidated and standalone f…

BSE Filing ↗
Board MeetingAJANTPHARM
2024
30Jul

Board Meeting

Consider and approve unaudited consolidated and standalone f…

BSE Filing ↗
Board MeetingAJANTPHARM
2024
2May

Board Meeting

consider and approve buy-back of Equity Shares and other mat…

BSE Filing ↗
DividendAJANTPHARM
2024
8Feb

₹26 / share

BSE Filing ↗
Board MeetingAJANTPHARM
2024
31Jan

Board Meeting

declaration of 2nd Interim Dividend for the financial year e…

BSE Filing ↗
Board MeetingAJANTPHARM
2023
31Oct

Board Meeting

Consider and approve Unaudited Consolidated and Standalone F…

BSE Filing ↗